AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
65 hedge funds and large institutions have $60.4M invested in AVEO Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 12 closing their positions.
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
3% more funds holding
Funds holding: 63 → 65 (+2)
5% more capital invested
Capital invested by funds: $57.7M → $60.4M (+$2.71M)
1% less call options, than puts
Call options by funds: $6.32M | Put options by funds: $6.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$6.02M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$880K |
| 3 |
Two Sigma Investments
New York
|
+$572K |
| 4 |
Renaissance Technologies
New York
|
+$552K |
| 5 |
State Street
Boston,
Massachusetts
|
+$500K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.94M |
| 2 |
Goldman Sachs
New York
|
-$398K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$235K |
| 4 |
Jane Street
New York
|
-$213K |
| 5 |
WG
Winton Group
London,
United Kingdom
|
-$149K |
AVEO Hedge Fund Activity: Q4 2020 in Review
65 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2020, worth a combined $60.4M — up 4.7% from $57.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new AVEO positions and 12 closed out — a net gain of 2 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was Sectoral Asset Management, adding an estimated $6.02M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $5.94M sold.
- 65 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2020, up from 63 in Q3 2020.
- Funds reported $60.4M of AVEO Pharmaceuticals, Inc. stock for Q4 2020, up 4.7% quarter-over-quarter.
- 14 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2020 and 12 closed out, a net change of +2 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2020 was Sectoral Asset Management, an estimated $6.02M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q4 2020 was Cormorant Asset Management, an estimated $5.94M sold.
Based on aggregated 13F filings for Q4 2020.